August Bioservices
August Bioservices is a U.S.-based, Nashville-headquartered CDMO providing fully integrated development, analytical, and cGMP manufacturing services exclusively for sterile injectable drug products, serving pharmaceutical and biotech sponsors from clinical through commercial scale.
- Company typePrivate
- Founded2020
- HeadquartersNashville, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What August Bioservices does
August Bioservices, LLC is a U.S.-based contract development and manufacturing organization (CDMO) headquartered in Nashville, Tennessee, specializing exclusively in sterile injectable drug products. Founded in 2020 through the rebranding of PMI BioPharma and led by CEO Jenn Adams, the company operates an integrated three-service model spanning product development (formulation, process development, technology transfer, and scale-up), analytical services (full USP <1> release testing, stability, elemental impurities, extractables and leachables, nitrosamines, container closure integrity), and cGMP manufacturing (1L–4000L formulation scale across seven filling lines for vials, syringes, and IV bags, plus large-scale lyophilization and automated end-of-line inspection, packaging, and serialization). The facility is compliant with FDA Sterile Injectable Guidance, EU GMP Annex 1, and an ICH-based Quality Management System, enabling service to both U.S. and European pharmaceutical and biotech sponsors.
The business model is professional-services-based: revenue is generated through negotiated, project-based CDMO contracts with pharmaceutical and biotech clients, spanning modalities that include small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles. Go-to-market is enterprise field sales with dedicated CDMO Business Development leadership, supported by attendance at major industry events (DCAT, CPHI, BIO, Contract Pharma, CDMO Live) and thought-leadership content in trade publications. The company has cumulatively raised approximately $88.6 million of institutional capital — including a $23.6 million Series A extension led by Polaris Partners (May 2021) and a $65 million Series B led by Oak HC/FT (December 2022) — alongside state grants, to fund a $64.7 million campus expansion that includes a 60,000 sq ft state-of-the-art commercial manufacturing facility, 180 planned new jobs over five years, and a 2025 strategic partnership with Optima for advanced fill-finish systems.
August Bioservices firmographics
Firmographics- Name
- August Bioservices
- Legal name
- August Bioservices, LLC
- Website
- https://augustbio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- August Bioservices is a U.S.-based, Nashville-headquartered CDMO providing fully integrated development, analytical, and cGMP manufacturing services exclusively for sterile injectable drug products, serving pharmaceutical and biotech sponsors from clinical through commercial scale.
- Ownership category
- akta.pro rank
August Bioservices industry classification
Industry- Product category
- Sterile Injectable CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where August Bioservices is headquartered
LocationHeadquarters
- HQ city
- Nashville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
August Bioservices business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: August Bioservices generates revenue through contract development and manufacturing organization (CDMO) services for pharmaceutical and biotech companies. Services span the full product lifecycle from early formulation development through commercial-scale manufacturing of sterile injectable drug products. Revenue is project-based with long-term contract relationships typical in the CDMO industry.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
August Bioservices product offering
Product offeringCore offering
August Bioservices is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, analytical testing, and cGMP manufacturing services focused exclusively on sterile injectable drug products. The company serves pharmaceutical and biotechnology clients across formulation development, process development and technology transfer, comprehensive analytical and microbiological testing, and sterile fill-finish manufacturing for vials, syringes, and IV bags at scales from 1L to 4000L.
Product overview
August Bioservices is a US-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, testing, and manufacturing services focused on sterile injectables. The company operates three interconnected service lines: Product Development Services (formulation, process development, technology transfer), Analytical Services (chemistry, microbiology, and characterization testing), and Manufacturing Services (sterile filling, inspection, packaging). Together these services span from early-stage lab-scale development through commercial-scale manufacturing for pharmaceutical and biotech clients.
Differentiator
Problem solved
Functional benefit
Products and services
- Product Development Services Scientific product development services for sterile injectables, including formulation development (liquid, homogenization, microfluidization, rotary evaporation, lab-scale lyophilization), process development and optimization, DoE and QbD study design and statistical analysis, and technology transfer and scale-up. Serves pharmaceutical and biotech clients developing modalities such as small molecules, peptides, enzymes, biologics, controlled substances, and lipid nanoparticles.
- Analytical Services On-site Chemistry, Microbiology, Raw Material, and Analytical Development laboratories performing full USP <1> release testing for injectables, stability testing across all ICH Zones, elemental impurity testing (ICPMS), residual solvent testing (GCMS), extractables and leachables, nitrosamines, photostability, thermal cycling, and container closure integrity testing. Supports CMC submission readiness for pharmaceutical and biotech clients.
- Manufacturing Services cGMP sterile injectable manufacturing services covering formulation at 1L to 4000L scale using stainless steel and single-use technology, sterile filling for vials, syringes, and IV bags (including drug-device combination products), lyophilization, and automated visual inspection, assembly, labeling, packaging, and serialization. Serves pharmaceutical and biotech clients from clinical through commercial supply.
Companies that use August Bioservices
Customer profileSegments2 records
Ideal customer profiles2 records
August Bioservices technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
August Bioservices partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- OptimastrategicAugust Bio partners with Optima to enhance fill-finish flexibility with advanced systems for vials, pre-filled syringes, and cartridges. The partnership provides state-of-the-art equipment including Optima isolated high-speed vial filler and syringe filler systems. Optima's Turnkey approach and flexibility of solutions created real added value for August Bio's manufacturing operations.
Scale indicators6 records
Recent moves12 records
Expansion highlights6 records
August Bioservices competitors and assessment
Company assessmentBroad incumbents
- Catalent: Catalent is one of the largest global CDMOs with deep sterile injectable fill-finish capabilities across vials, syringes, and prefilled devices. It competes head-to-head with August Bio for clinical and commercial sterile injectable programs but operates a much broader global network and larger customer book.
- Lonza: Lonza is a global CDMO leader spanning small molecules, biologics, and cell/gene therapy, including sterile injectable drug product manufacturing. It is a relevant incumbent peer given August Bio's stated biologics and complex formulation capabilities.
- Thermo Fisher Scientific (Patheon): Thermo Fisher's Pharma Services segment (including Patheon) offers large-scale sterile injectable development and manufacturing alongside oral solid dose and API services. A broader incumbent that competes with August Bio for commercial-scale sterile programs.
- Recipharm: Recipharm is a European-headquartered CDMO with sterile injectable manufacturing capabilities alongside other dosage forms. A relevant incumbent competitor for cross-regional pharma sponsors.
- Piramal Pharma Solutions: Piramal operates a global sterile injectable CDMO network (including its Lexington facility acquired from Coldstream). Comparable in modality coverage and customer segment to August Bio, though at larger scale.
- Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO expanding into sterile fill-finish services. Represents an emerging large competitor in the biologics injectable space where August Bio is also investing.
- Curia (formerly AMRI): Curia is a CDMO providing sterile injectable development and manufacturing services as part of a broader contract services portfolio. A comparable mid-to-large scale peer across multiple sterile injectable programs.
Direct peers
- Grand River Aseptic Manufacturing: Grand River is a U.S.-based CDMO focused on sterile injectable fill-finish for vials, syringes, and lyophilized products. Closely comparable to August Bio in scale, scope, and customer base of small-to-mid pharma and biotech sponsors.
- Alcami: Alcami is a U.S.-based CDMO offering sterile injectable development, manufacturing, and analytical services. Directly comparable to August Bio in services offered and target customer profile of small-to-mid pharma.
- Emergent BioSolutions: Emergent operates contract sterile injectable manufacturing through its CDMO business along with proprietary products. A relevant peer for U.S.-based sterile fill-finish services targeting vaccine and injectable biologics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
August Bioservices social profiles
Digital presenceAugust Bioservices compliance and trust
Trust signalCompliance3 records
August Bioservices financial estimates
Financial estimateRevenue estimate
Valuation estimate
August Bioservices leadership team
Management profileNumber of profiles
Profiles13 records
August Bioservices funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
August Bioservices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about August Bioservices
What does August Bioservices do?
August Bioservices is a U.S.-based Contract Development and Manufacturing Organization (CDMO) providing fully integrated drug development, analytical testing, and cGMP manufacturing services focused exclusively on sterile injectable drug products. The company serves pharmaceutical and biotechnology clients across formulation development, process development and technology transfer, comprehensive analytical and microbiological testing, and sterile fill-finish manufacturing for vials, syringes, and IV bags at scales from 1L to 4000L.
Is August Bioservices a public or private company?
August Bioservices is a private company. It is classified as venture growth investor backed and is currently operating.
When was August Bioservices founded?
August Bioservices was founded in 2020. It employs 51 to 100 people.
Where is August Bioservices based?
August Bioservices is headquartered in Nashville, United States, in the North America region.
How does August Bioservices make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are August Bioservices's main competitors?
Broad incumbents on record are Catalent, Lonza, Thermo Fisher Scientific (Patheon), Recipharm, Piramal Pharma Solutions, Samsung Biologics and Curia (formerly AMRI). Direct peers are Grand River Aseptic Manufacturing, Alcami and Emergent BioSolutions.
Does August Bioservices have an API?
No public API is recorded for August Bioservices.
What industry is August Bioservices in?
August Bioservices's product category is Sterile Injectable CDMO Services. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.